FDA Grants Groundbreaking Pioneering Approval for Opdivo Qvantig Injection in 5 Adult Solid Tumor Indications

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection for subcutaneous use. This innovative combination product…

Read MoreFDA Grants Groundbreaking Pioneering Approval for Opdivo Qvantig Injection in 5 Adult Solid Tumor Indications